qiaoping xu

Mrs. qiaoping xu


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2025 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
BJBowen Jin
Bowen Jin
ZMZehua Miao
Zehua Miao
JPJunjie Pan
Junjie Pan
ZZZhen Zhang
Zhen Zhang
YYYibei Yang
Yibei Yang
QXqiaoping xu
qiaoping xu
Ovarian cancer (OC) is one of the three most common malignant tumors of the female reproductive system, with the highest mortality rate among gynecologic malignancies. Like other tumors, OC cells undergo metabolic reprogramming phenomenon and convert glucose metabolism into “aerobic glycolysis” and generate a high concentration of lactate, i.e., the “Warburg effect”, which provides a large amount of energy and corresponding intermediary metabolites for their survival, reproduction and metastasis. Numerous studies have shown that targeted inhibition of aerobic glycolysis and lactate metabolism is a promising strategy to enhance the sensitivity of cancer cells to immunotherapy. Therefore, this review summarizes the metabolic features of glycolysis in OC cells and highlights how abnormal lactate concentration affects the differentiation, metabolism, and function of infiltrating immune cells, which contributes to immunosuppression, and how targeted inhibition of this phenomenon may be a potential strategy to enhance the therapeutic efficacy of OC.

26 July 2024 in International Journal of Oncology
Verified
Journal Article
Open access
PDF file
YYYibei Yang
Yibei Yang
FGFeng Gao
Feng Gao
LRLanqi Ren
Lanqi Ren
NRNing Ren
Ning Ren
JPJunjie Pan
Junjie Pan
QXqiaoping xu
qiaoping xu
Breast cancer (BC) is a major malignant tumor in females and the incidence rate of BC has increased worldwide in recent years. N6‑methyladenosine (m6A) is a methylation modification that occurs extensively in eukaryotic RNA. The abnormal expression of m6A and related regulatory proteins can activate or inhibit certain signal pathways or oncogenes, thus affecting the proliferation, metastasis and prognosis of BC. Numerous studies have shown that m6A regulator disorder exists in BC, and this disorder can be reversed. Therefore, m6A is predicted as a potential therapeutic target for BC. However, the molecular mechanism of m6A RNA methylation regulating the occurrence and development of BC has not been comprehensively elucidated. In this review article, the functions of various m6A regulators and the specific mechanisms of certain regulators of the progress of BC were summarized. Furthermore, the dual role of RNA methylation in tumor progression was discussed, concluding that RNA methylation can not only lead to tumorigenesis but at times give rise to inhibition of tumor formation. In addition, further comprehensive analysis on mechanisms of m6A regulators in BC is conducive to screening effective potential targets and formulating targeted treatment strategies, which will provide new methods for the prevention and treatment of BC.

4 August 2025 in Cancer Cell International
Verified
Journal Article
Open access
LLLi Liao
Li Liao
XXXiaoqiang Xu
Xiaoqiang Xu
YCYu Cao
Yu Cao
KTKezhong Tang
Kezhong Tang
QXqiaoping xu
qiaoping xu
Pancreatic cancer (PC) is a highly invasive malignant tumor associated with significant mortality rates, primarily due to challenges in early diagnosis, high invasiveness, and pronounced drug resistance. In recent years, N6-methyladenosine (m6A), one of the most abundant RNA modifications in eukaryotic cells, has been shown to play a critical role in various RNA processes, including alternative splicing, maturation, stability, translation and degradation. m6A is dynamically and reversibly regulated by its methyltransferases, demethylases and m6A-binding proteins, which have been reported to significantly influence the development and progression of various cancers, including PC. We review the latest advancements in m6A regulators and their roles in PC, and introduce the mechanism and signaling pathways of m6A factors affecting PC occurrence and development. Furthermore, we summarize the potential applications of m6A regulators in improving drug resistance and immunotherapy efficacy, as well as the therapeutic promise of small-molecule inhibitors targeting m6A-related proteins, to provide innovative methods and strategies for the diagnosis and treatment of pancreatic cancer.

23 February 2021 in Cost Effectiveness and Resource Allocation
Verified
Journal Article
Open access
PDF file
QXqiaoping xu
qiaoping xu
LYLi Yuanyuan
Li Yuanyuan
ZJZhu Jiejing
Zhu Jiejing
LJLiu Jian
Liu Jian
LQLi Qingyu
Li Qingyu
YWYan Wei
Yan Wei
Breast cancer is the most common cancer among women in China. Amplification of the Human epidermal growth factor receptor type 2 (HER2) gene is present and overexpressed in 18–20% of breast cancers and historically has been associated with inferior disease-related outcomes. There has been increasing interest in de-escalation of therapy for low-risk disease. This study analyzes the cost-effectiveness of Doxorubicin/ Cyclophosphamide/ Paclitaxel/ Trastuzumab (AC-TH) and Docetaxel/Carboplatin/Trastuzumab(TCH) from payer perspective over a 5 year time horizon. A half-cycle corrected Markov model was built to simulate the process of breast cancer events and death occurred in both AC-TH and TCH armed patients. Cost data came from studies based on a Chinese hospital. One-way sensitivity analyses as well as second-order Monte Carlo and probabilistic sensitivity analyses were performed.The transition probabilities and utilities were extracted from published literature, and deterministic sensitivity analyses were conducted. We identified 41 breast cancer patients at Hangzhou First People’s Hospital, among whom 15 (60%) had a partial response for AC-TH treatment and 13 (81.25%) had a partial response for TCH treatment.No cardiac toxicity was observed. Hematologic grade 3 or 4 toxicities were observed in 1 of 28 patients.Nonhematologic grade 3 or 4 toxicities with a reverse pattern were observed in 6 of 29 patients. The mean QALY gain per patient compared with TCH was 0.25 with AC-TH, while the incremental costs were $US13,142. The incremental cost-effectiveness ratio (ICER) of AC-TH versus TCH was $US 52,565 per QALY gained. This study concluded that TCH neoadjuvant chemotherapy was feasible and active in HER2-overexpressing breast cancer patients in terms of the pathological complete response, complete response, and partial response rates and manageable toxicities.

1 January 2025 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
YZYidong Zhou
Yidong Zhou
FTFei Tong
Fei Tong
BJBowen Jin
Bowen Jin
JPJunjie Pan
Junjie Pan
NRNing Ren
Ning Ren
QXqiaoping xu
qiaoping xu
Zhou Y, et al. J Gynecol Oncol. 2025 Feb;36:e63. https://doi.org/10.3802/jgo.2025.36.e63

4 November 2025 in Cellular Oncology
Verified
Journal Article
Open access
PDF file
KYKexin Yu
Kexin Yu
YJYuanxiang Jin
Yuanxiang Jin
YZYidong Zhou
Yidong Zhou
QXqiaoping xu
qiaoping xu
Hepatocellular carcinoma (HCC) remains one of the most lethal malignancies worldwide, with its pathogenesis involving complex biological processes such as DNA damage, epigenetic modification and oncogene mutation. Over the past two decades, the role of long non-coding RNAs (lncRNAs) in the occurrence, metastasis and progression of HCC has received increasing attention. As an important noncoding RNA molecule, lncRNAs play a key role in regulating gene expression, affecting RNA transcription and mRNA stability. This review elucidates the potential pathogenic processes of HCC and elaborates on the synthesis mechanisms of the above three non-coding RNAs. It comprehensively summarizes various non-coding RNAs that have been identified as playing key regulatory roles in HCC, as well as how these non-coding RNAs affect disease progression by regulating gene expression and protein functions. For example: lncRNAs such as NEAT1, DSCR8, PNUTS, HULC, and HOTAIR can play different roles in the proliferation, migration, and apoptosis of HCC cells in different ways. lncRNAs such as HClnc1, LINC01343, FAM111A-DT, CERS6–AS1, and TLNC1 significantly affect the progression of HCC by regulating key signaling axes or protein functions, and are closely related to the prognosis of patients. In addition, we also discuss the potential of lncRNAs as therapeutic targets for HCC, such as: lncRNA MIR31HG, CASC2c, and lncRNA AC115619. Furthermore, we also explore the application prospects of lncRNAs as potential biomarkers and therapeutic targets, providing new perspectives and directions for future HCC research.